

Table 1 ONGOING AND PLANNED PrEP TRIALS AS OF APRIL 2008

Location	Sponsor/ Funder	Population (mode of exposure)	Intervention Arms	PrEP strategy(ies) being tested	Status/Expected completion
United States	CDC	400 men who have sex with men (penile/rectal)	1	Tenofovir disoproxil fumarate (TDF)	Fully enrolled – Ongoing 2009
Thailand	CDC	2,400 injecting drug users (parenteral)	1	TDF	Enrolling / 2009
Botswana	CDC	1,200 heterosexual men and women (penile and vaginal)	1	TDF+emtricitabine (FTC) (switched from TDF Q1 2007)	Enrolling / 2010
Peru, Ecuador, US, additional sites TBD (iPrEX Study)	NIH, BMGF	3,000 men who have sex with men (penile/rectal)	1	TDF+FTC	Enrolling / 2010
Kenya, Uganda (Partners Study)	BMGF	3,900 serodiscordant couples (penile and vaginal)	2	TDF; TDF + FTC	Planning / 2012 Anticipated start Q2/2008
Kenya, Malawi, South Africa, Tanzania (FEMPrEP)	FHI, USAID	3,900 high-risk women (vaginal)	1	TDF+FTC	Planning / 2011 Anticipated start Q3/2008
Malawi, South Africa, Zambia, Zimbabwe (VOICE Study)	MTN, NIH	4,200 sexually active women (vaginal)	3	TDF; TDF+FTC; TDF gel	Planning / 2011 Anticipated start Q4/2008

BMGF – Bill & Melinda Gates Foundation; CDC - US Centers for Disease Control; FHI – Family Health International; MTN – Microbicide Trials Network; NIH – US National Institutes of Health; USAID – United States Agency for International Development